New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage);   - solution for inhalation - 2.5mg/2.5ml - active: salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage);   - solution for inhalation - 5mg/2.5ml - active: salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

Philippines - English - FDA (Food And Drug Administration)

pharex health corporation - salbutamol (as sulfate) , ipratropium (as bromide) - solution for inhalation - 2.5mg + 500mcg / 2.5ml

United States - English - NLM (National Library of Medicine)

medical supply distribution, llc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - indications and usage   ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. contraindications   ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of  hypersensitivity to any of its components, or to atropine and its derivatives. read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been prescribed. contact them if you have additional questions. store ipratropium bromide and albuterol sulfate inhalation solution between

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - salbutamol sulfate; ipratropium bromide - nebuliser liquid - 1mg/1ml ; 200microgram/1ml

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

neutec inhaler ireland ltd. - ipratropium bromide monohydrate 0,522 mg - eq. ipratropium bromide 0,5 mg; salbutamol sulfate 3,012 mg - eq. salbutamol 2,5 mg - nebuliser solution - salbutamol and ipratropium bromide

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - salbutamol sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - salbutamol -